Oticon president satisfied with FDA approval: "A huge milestone"

An approval from the US FDA for Oticon Medical's cochlear implant system Neuro can help the Danish company kick down the door to the US market for several products. The US approval might also pave the way for the products to become accessible outside the US, President Jes Olsen states.

Photo: Jens Dresling

Thursday is a happy day for Danish company Demant's bone-anchored division Oticon Medical, which has received approval for the company's cochlear implant system Neuro by the US Food and Drug Administration (FDA).

This process has been ongoing for many years, and access to the US market means that Oticon Medical will at least be doubling its market accessibility for the Neuro products.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs